CO6270329A2 - Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa - Google Patents

Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa

Info

Publication number
CO6270329A2
CO6270329A2 CO10053517A CO10053517A CO6270329A2 CO 6270329 A2 CO6270329 A2 CO 6270329A2 CO 10053517 A CO10053517 A CO 10053517A CO 10053517 A CO10053517 A CO 10053517A CO 6270329 A2 CO6270329 A2 CO 6270329A2
Authority
CO
Colombia
Prior art keywords
lactose
pharmaceutically acceptable
combination
oract
strogen
Prior art date
Application number
CO10053517A
Other languages
English (en)
Inventor
Sabine Fricke
Manuela Pfeifer
Claus Claussen
Ralf Ladwig
Beate Burglen
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6270329A2 publication Critical patent/CO6270329A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

Los gestagenos, con preferencia dienogest, acetato de clormadinona o levornogetrel en combinacion con estrogenos tales como, por ejemplo, etinilestradiol, 17ß-estradiol o valerato de estradiol y uno o varios excipientes/portadores farmacéuticamente aceptables realizan una anticoncepcion oral sin lactosa. Se da una posibilidad para mejorar la prevencion de la intolerancia a la glucosa en un factor que eventualmente contribuye con la mejoria, incluso en cuanto a costosos ensayos de la intolerancia a la glucosa. La invencion también es apropiada para un uso prolongado.
CO10053517A 2007-11-05 2010-05-05 Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa CO6270329A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07021465A EP2055306A1 (de) 2007-11-05 2007-11-05 Verwendung eines Gestagens in Kombination mit einem Estrogen und einem oder mehreren pharmazeutisch annehmbaren hilfsstoffen/Trägern zur laktosefreien oralen Kontrazeption

Publications (1)

Publication Number Publication Date
CO6270329A2 true CO6270329A2 (es) 2011-04-20

Family

ID=39016019

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10053517A CO6270329A2 (es) 2007-11-05 2010-05-05 Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa

Country Status (31)

Country Link
EP (3) EP2055306A1 (es)
JP (1) JP2011502136A (es)
KR (1) KR20100103794A (es)
CN (1) CN101848716B (es)
AR (1) AR069195A1 (es)
AT (1) AT12800U1 (es)
AU (1) AU2008324549A1 (es)
BR (1) BRPI0819189A2 (es)
CA (1) CA2704523A1 (es)
CO (1) CO6270329A2 (es)
CR (1) CR11413A (es)
DE (1) DE202007019049U1 (es)
DK (1) DK2217243T3 (es)
DO (1) DOP2010000130A (es)
EA (1) EA201000749A1 (es)
EC (1) ECSP10010152A (es)
ES (1) ES2511841T3 (es)
HK (1) HK1145289A1 (es)
HR (1) HRP20140962T1 (es)
IL (1) IL205349A0 (es)
MX (1) MX2010004975A (es)
NZ (1) NZ585065A (es)
PA (1) PA8803001A1 (es)
PE (1) PE20091020A1 (es)
PL (1) PL2217243T3 (es)
PT (1) PT2217243E (es)
SG (1) SG188118A1 (es)
TW (1) TW200936142A (es)
UY (1) UY31454A1 (es)
WO (1) WO2009059690A1 (es)
ZA (1) ZA201004024B (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368373A1 (en) * 1988-10-13 1990-05-16 Akzo Nobel N.V. Multi-phase contraceptive preparation
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
DK95093D0 (da) * 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
JPH1171268A (ja) * 1997-08-28 1999-03-16 Kayaku:Kk 性ホルモン含有錠剤
CA2260673A1 (en) 1999-02-04 2000-08-04 Natrel Inc. A process for making a lactose-free milk without negatively affecting the organoleptic properties thereof; and milk so processed
DE10043846A1 (de) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-Methylensteroide, Verfahren zu deren Herstellung und diese Verbindung enthaltende pharmazeutische Zusammensetzungen
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
EP1670440B1 (en) 2003-09-29 2014-04-30 Novo Nordisk Femcare AG Hrt formulations
JP4880465B2 (ja) 2003-09-29 2012-02-22 ノボ・ノルディスク・フェムケア・アーゲー 向上した安定性のプロゲストーゲン製剤
CN1672685A (zh) * 2004-03-26 2005-09-28 董可娟 一种新的避孕药物
DE102004019406A1 (de) * 2004-04-19 2005-11-03 Schering Ag 17α-Fluorsteroide
DE102004026670A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat
DE102004026671A1 (de) * 2004-05-28 2005-12-15 Grünenthal GmbH Darreichungsform zur hormonalen Kontrazeption
EP1690543A1 (de) * 2005-02-15 2006-08-16 Schering AG Pharmazeutisches Präparat zur Kontrazeption
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest

Also Published As

Publication number Publication date
AU2008324549A1 (en) 2009-05-14
PL2217243T3 (pl) 2014-12-31
TW200936142A (en) 2009-09-01
DE202007019049U1 (de) 2010-05-12
IL205349A0 (en) 2010-12-30
CN101848716B (zh) 2012-11-28
SG188118A1 (en) 2013-03-28
AT12800U1 (de) 2012-11-15
CN101848716A (zh) 2010-09-29
MX2010004975A (es) 2010-05-24
NZ585065A (en) 2012-06-29
EA201000749A1 (ru) 2010-12-30
PE20091020A1 (es) 2009-08-15
DE202007019049U8 (de) 2010-09-30
KR20100103794A (ko) 2010-09-28
EP2774614A1 (de) 2014-09-10
CR11413A (es) 2010-06-17
EP2055306A1 (de) 2009-05-06
PT2217243E (pt) 2014-09-24
JP2011502136A (ja) 2011-01-20
BRPI0819189A2 (pt) 2015-05-26
PA8803001A1 (es) 2009-06-23
UY31454A1 (es) 2009-05-29
EP2217243A1 (de) 2010-08-18
ES2511841T3 (es) 2014-10-23
HRP20140962T1 (hr) 2014-12-05
HK1145289A1 (en) 2011-04-15
AR069195A1 (es) 2010-01-06
DOP2010000130A (es) 2010-07-31
ECSP10010152A (es) 2010-06-29
DK2217243T3 (da) 2014-10-20
CA2704523A1 (en) 2009-05-14
EP2217243B1 (de) 2014-08-06
ZA201004024B (en) 2012-11-28
WO2009059690A1 (de) 2009-05-14

Similar Documents

Publication Publication Date Title
PE20061415A1 (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato
PE20080273A1 (es) Composicion farmaceutica que contiene un progestageno, un estrogeno y un acido tetrahidrofolico
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
IN2012DN04867A (es)
PE20070208A1 (es) Anticoncepcion oral con trimegestona
ATE493132T1 (de) Arzneimittel umfassend wenigstens ein gestagen
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
BRPI0512993A (pt) uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto
CL2011003172A1 (es) Composicion farmaceutica que comprende a) un excepiente, b) al menos un precursor de esteroides sexuales, c) al menos un modulador selectivo del receptor de estrogenos o una antiestrogeno y no contiene una progestina y/o un estrogeno; kit farmaceutico; y uso para reducir o eliminar sofocos, sintomas vasomotores y sudores nocturnos.
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
MX2010004353A (es) Combinación anticonceptiva oral entiemética.
CR10259A (es) Metodos para la prevencion y tratamiento de condiciones que surgen de deficiencia de estrogeno local
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
JP2008515909A5 (es)
AR121864A1 (es) Composiciones anticonceptivas con efectos adversos reducidos
CO5580789A2 (es) Composicion que comprende una combinacion de un inhibidor de aromatasa, una progestina y un estrogeno y su uso para el tratamiento de endometriosis
AR049196A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
CO6270329A2 (es) Uso de gestageno en combinacion con un estrogeno y uno o varios excipientes / portadores farmaceuticamente acepptables para la anticoncepcion oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
DOP2006000037A (es) Forma farmacológica peroral sólida para la anticoncepción
DE602004018921D1 (de) D dienogest
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
CR11211A (es) Estratienos 8-beta-sustituidos como estrogenos de accion selectiva

Legal Events

Date Code Title Description
FC Application refused